Day: April 25, 2025

ASHBURN, Va., April 25, 2025 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced that it will report first quarter 2025 financial results on Friday, May 9, 2025. Management will host a webcast to discuss the Company’s financial results and business outlook at 9:30 a.m. ET.  What: Telos Corporation First Quarter 2025 Financial Results Webcast  When: Friday, May 9, 2025  Time: 9:30 a.m. ET  Webcast: https://investors.telos.com/news-and-events/eventsAn on-demand replay of the webcast will be available on the Company’s investor relations website. About Telos CorporationTelos Corporation (NASDAQ: TLS) empowers and protects the world’s most security-conscious organizations with solutions...

HUHTAMÄKI OYJ MANAGERS’ TRANSACTIONS 25.4.2025 AT 15:20 EEST Huhtamäki Oyj – Managers’ Transactions ____________________________________________Person subject to the notification requirementName: Pekka VauramoPosition: Member of the Board/Deputy memberIssuer: Huhtamäki OyjLEI: 5493007050SJVMXN6L29Notification type: INITIAL NOTIFICATIONReference number: 105281/11/10 ____________________________________________Transaction date: 2025-04-25Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009000459Nature of transaction: ACQUISITION Transaction details(1): Volume: 2500 Unit price: 32.12 EUR Aggregated transactions (1): Volume: 2500 Volume weighted average price: 32.12 EUR About Huhtamaki Huhtamaki is a leading global provider of sustainable packaging solutions for consumers around the world. Our innovative...

SOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting a poster at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, “First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-L in acute myeloid leukemia (CertainT-1).” Chris Ehrlich, CERo Therapeutics’ CEO, commented, “We look forward to the opportunity to discuss our study protocol at one of the most prestigious oncology conferences in the world. We believe that CER-1236 presents a...

Harju County Court made an interim judgement today, finding that the claim filed by Tallinn University of Technology against Tallinna Vesi for compensation for damages resulting from the breach of obligations under the water service contract is generally justified, it isn´t expired, and the proceedings must continue regarding the amount of the claim. Tallinna Vesi disagrees with the county court’s settlement. The company has found from the beginning of the dispute that it has not breached the contracts concluded with its clients and that its pricing has been in accordance with the applicable legal acts. The disputed situation was caused by an unclear regulation during the period from November 1, 2010, to November 30, 2019. The legal acts underlying the pricing of water services changed in 2010 – previously, the price was set by the...

WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer Research (AACR) 2025 Annual Meeting taking place in Chicago. “We welcome the opportunity to present updated results from these programs that represent our exciting pipeline of potential best-in-class targeted therapies,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “These data demonstrate Cogent’s ability to discover and advance novel therapies for rare disease populations with high unmet medical need, and we look forward to continuing to advance these candidates.” Poster Details Title: Identification...

News Release April 25, 2025 BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the completion of a directed share capital raise of 25,000,000 new shares at the market offer price of DKK 1.3402 per share raising gross proceeds of DKK 33,505,000 million. Jens Due Olsen, Chair of the Board, says: “I am pleased to have been elected as Chair of the Board of BioPorto. The capital raise will help the company reach its objective of advancing the commercial launch of ProNephro AKI NGAL in the US and with the preparation to apply for FDA clearance of the test for adult use. I look forward contributing...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on providing customized investment solutions and advisory and data services, today announced that it has raised $705 million for StepStone Tactical Growth Fund IV (“STGF IV” or the “Fund”), the firm’s fourth fund focused on opportunities within the growth equity market. The Fund had strong participation from a range of investor types including sovereign wealth funds, public pensions, superannuation funds, funds-of-funds, family offices, and private wealth platforms. Through STGF IV, StepStone partners with leading growth equity sponsors in the technology and healthcare sectors. The Fund pursues founder-led businesses outside the traditional venture capital ecosystem that exhibit rapid topline growth,...

TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc’s Palmitoylethanolamide (“PEA”). This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment. Eating disorders are...